OGEN - oragenics.com Market Cap to Sales Volume

Corporate company logo of Oragenics, Inc. (OGEN)

Oragenics, Inc. (OGEN) faces early-stage development risks and a capital deficit. The company is penetrating the niche of intranasal agents for brain injuries, where competition is absent. The price-to-sales ratio visualizes these processes, and its current value is 372.50. Geopolitical tensions and the need for new antibiotics could strengthen government support for the business.

Oragenics, Inc. (OGEN): Price-to-Revenue Ratio from 07/04/2022 to 11/15/2024

Metric breakdowns and analytics for Oragenics, Inc. (OGEN)

- market price and analyst price targets:
Stock Quotes Oragenics Inc.|OGEN - Consensus Target
- market capitalization statistics:
Market Value Oragenics|OGEN - Enterprise Value
- book capitalization information:
Net Assets per Share Oragenics|OGEN - Company Book Value|Market-to-Book Ratio oragenics.com|OGEN - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio Oragenics, Inc.|OGEN - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient oragenics.com|OGEN - Company Debts|Debts to Book Value Oragenics|OGEN - Company Long-Term Debt|Company Short-Term Loans and Borrowings Oragenics|Quick Ratio oragenics.com
- net income and valuation ratios data:
OGEN - Net Profit|Projected Net Profit Oragenics, Inc.|OGEN - P/E Multiple|Projected Price to Earnings Ratio Oragenics Inc.|OGEN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Oragenics|OGEN - Operating profit EBITDA|Net earnings per share for the last four quarters Oragenics|OGEN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months oragenics.com|OGEN - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Oragenics, Inc.
- total revenue and sales volume data:
OGEN - Company Sales|Company Future Revenue oragenics.com|OGEN - P/S Multiple|Market Cap to Expected Sales Ratio Oragenics
Fundamental company analysis:OGEN - Oragenics Inc.
Manufactured products of Oragenics, Inc.

The P/S ratio reflects the market value of a business relative to its annual revenue, allowing for an assessment of asset monetization efficiency regardless of current earnings. For the growing Oragenics, Inc. (OGEN), which develops neuroprotective agents, this revenue-based valuation on GURU.Markets demonstrates a premium for future success in sports medicine, where a historical analysis of the metric helps determine a fair entry threshold for capital protection.

Competitors of Oragenics, Inc.

Market Cap to Revenue summittxinc.com SMMT|Moderna - Market Cap to Revenue|Market Cap to Sales Volume PCVX (Vaxcyte Inc)|Tarsus Pharma - P/S Multiple|Price-to-Revenue Coefficient CorMedix Therapeutics CRMD|Seres Therapeutics (MCRB) - Price-to-Revenue Ratio|Price to Sales sperotherapeutics.com (SPRO)|Price-to-Revenue Ratio SCYNEXIS Inc|Market Cap to Revenue Ratio ANTX (AN2 Bio)|Price-to-Revenue Ratio PolyPid Ltd. (PYPD)|Price-to-Revenue Coefficient YS Biopharma Co., Ltd.|Price-to-Revenue Ratio Iterum Therapeutics ITRM|BiomX Inc (PHGE) - Price to Sales|SNGX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio SXTP (60 Degrees Pharmaceuticals)|OPGN: P/S Multiple